Cytokinetics clinical trials we track

Check company identity source

Phase 3 6 trials

Phase 2 / 3 2 trials

Phase 2 2 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Incidence of adverse events observed during dosing of aficamten in patients with HCM Description: Patient incidence of reported Adverse Events (AEs) Time frame: Baseline to End of study, up to 5 years. After: Measure: Incidence of adverse events observed during dosing of aficamten in patients with HCM Description: Patient incidence of reported Adverse Events (AEs) Time frame: Baseline to End of study, up to 5 years Measure: Incidence of serious adverse events observed during dosing of aficamten in patients with HCM Description: Patient incidence of reported Serious Adverse Events (SAEs) Time frame: Baseline to End of study, up to 5 years Measure: Incidence of left ventricular ejection fraction (LVEF) < 50% observed during dosing of aficamten in patients with HCM Description: Patient incidence of reported LVEF \<50% Time frame: Baseline to End of study, up to 5 years.

Primary completion date changed

Before: Mar 2028. After: Mar 2029.

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Change in peak oxygen uptake (pVO2) by cardiopulmonary exercise testing (CPET). After: Measure: Change in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET).

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Change in peak oxygen uptake (pVO2) by cardiopulmonary exercise testing (CPET). After: Measure: Change From Baseline in pVO2 at Week 24.

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Incidence of adverse events observed during dosing of CK--3773274 in patients with HCM. After: Measure: Incidence of Adverse Events (AEs) Measure: Incidence of Left Ventricular Ejection Fraction (LVEF) < 50% Measure: Incidence of Serious Adverse Events (SAEs).

Check registry source